Information on how to access XELJANZ®▼ (tofacitinib citrate) prescribing information and adverse event reporting can be found at the bottom of the page.
In this video, Dr Peter Irving and Dr Sailish Honap explain the rationale for Janus Kinase (JAK) inhibition in UC, discuss the safety and efficacy of XELJANZ in UC and share multicentre clinical experience from four gastroenterology centres in the UK (Guy's and St Thomas' Hospital, Royal Devon and Exeter Hospital, Oxford University Hospitals and King's College London Hospital).
XELJANZ Risk Minimisation Programme (RMP) materials, including a Patient Alert Card, Prescriber Checklists and a Prescriber Brochure are available from https://www.medicines.org.uk/emc/. Patients treated with XELJANZ should be given the Patient Alert Card.
Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.
PP-PFE-GBR-2809. October 2020
Sign up now
Visit our new HCP events hub to view and register for the latest Pfizer organised promotional virtual meetings that may be of interest.
PP-PFE-GBR-XXXX. August 2021.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020